BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2026)

BioNexus Gene Lab (BGLC) reported Invested Capital of $54375.0 for Q1 2026, up 59.7% sequentially from $34049.0 in Q1 2022.

BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2026) Analysis & Trends

BioNexus Gene Lab (BGLC) has 6 years of Invested Capital data on file, last reported at $54375.0 in Q1 2026.

For the quarter ending Q1 2026, Invested Capital changed N/A year-over-year to $54375.0; the trailing twelve-month figure through Mar 2026 stood at $54375.0 (changed N/A YoY), and the FY2021 full-year result was $34038.0, down 43.59% from the prior year.
Invested Capital grew to $54375.0 in Q1 2026, from $34049.0 in the prior quarter.
In the past five years, Invested Capital ranged from a high of $54375.0 in Q1 2026 to a low of $34049.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Linde	237.95 Bn	233.99 Bn	4.26 Bn	4.82 Bn
2	Sherwin Williams	78.17 Bn	77.95 Bn	2.78 Bn	2.38 Bn
3	Ecolab	76.02 Bn	75.37 Bn	1.85 Bn	870.40 Mn
4	Air Products & Chemicals	66.38 Bn	65.43 Bn	987.40 Mn	244.30 Mn
5	Ppg Industries	26.02 Bn	24.40 Bn	1.66 Bn	736.00 Mn
6	LyondellBasell Industries	22.51 Bn	19.87 Bn	701.00 Mn	226.00 Mn
7	Chemical & Mining Co Of Chile	19.70 Bn	15.83 Bn	778.60 Mn	-
8	International Flavors & Fragrances	19.51 Bn	18.95 Bn	1.02 Bn	1.08 Bn
9	DuPont de Nemours	18.80 Bn	18.71 Bn	602.00 Mn	40.00 Mn
10	BioNexus Gene Lab	2.82 Mn	-1.14 Mn	-790.00	54,375.00

Download Data